Orchestra BioMed launches public offering of common stock
OBIO•Orchestra BioMed launched an underwritten public offering of common stock, with all shares being offered by the company. Net proceeds will support AVIM Therapy and Virtue SAB programs, including pivotal trials, as well as other development and general corporate purposes.
1. Offering details
Underwriters will have a 30-day option to purchase additional shares equal to up to 15% of the offering. Piper Sandler and TD Cowen are joint bookrunning managers, and BTIG is a bookrunner.
